Climb Bio, Inc. (NASDAQ:CLYM) Given Consensus Recommendation of “Buy” by Analysts

Climb Bio, Inc. (NASDAQ:CLYM) has been given an average recommendation of “Buy” by the fourteen analysts that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, ten have issued a buy rating and three have issued a strong buy rating on the company. The average 1 year target price among brokers that have covered the stock in the last year is $22.00.

Several equities analysts recently weighed in on the stock. Robert W. Baird set a $21.00 price target on shares of Climb Bio in a research report on Wednesday, May 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Climb Bio in a research report on Friday, July 17th. Mizuho assumed coverage on shares of Climb Bio in a research note on Wednesday, April 15th. They issued an “outperform” rating and a $18.00 target price on the stock. BTIG Research increased their target price on shares of Climb Bio from $19.00 to $20.00 and gave the company a “buy” rating in a research report on Thursday, June 11th. Finally, Wall Street Zen upgraded shares of Climb Bio from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th.

Hedge Funds Weigh In On Climb Bio

Institutional investors and hedge funds have recently bought and sold shares of the company. Seven Fleet Capital Management LP purchased a new stake in Climb Bio in the fourth quarter worth $306,000. ArchPoint Investors purchased a new position in shares of Climb Bio during the 4th quarter valued at $486,000. 683 Capital Management LLC purchased a new position in shares of Climb Bio during the 4th quarter valued at $807,000. Peapod Lane Capital LLC lifted its position in shares of Climb Bio by 0.7% during the 4th quarter. Peapod Lane Capital LLC now owns 565,992 shares of the company’s stock valued at $2,264,000 after buying an additional 4,126 shares during the last quarter. Finally, Balyasny Asset Management L.P. bought a new position in shares of Climb Bio during the 4th quarter worth $57,000. 69.76% of the stock is owned by institutional investors.

Climb Bio Price Performance

Shares of NASDAQ:CLYM opened at $12.17 on Friday. The company has a market capitalization of $696.89 million, a PE ratio of -15.60 and a beta of 0.07. The business has a fifty day moving average price of $12.18 and a two-hundred day moving average price of $8.97. Climb Bio has a 1 year low of $1.36 and a 1 year high of $14.41.

Climb Bio (NASDAQ:CLYM) last announced its earnings results on Thursday, May 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.06. Sell-side analysts anticipate that Climb Bio will post -0.87 earnings per share for the current year.

About Climb Bio

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.